Showing results (21-30 of 349) with videos related to
Sort By:
Pageof 35
Acta Neurologica Scandinavica. Supplementum|January 1, 1983
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's diseaseG M Stern, A J Lees, R J Hardie, et al.Lancet (London, England)|July 28, 1984
Effect of L-dopa on course of Parkinson's diseaseL Curtis, A J Lees, G M Stern, et al.Clinical Neuropharmacology|June 1, 1991
The motor response to repeated apomorphine administration in Parkinson's diseaseA J Hughes, S Bishop, G M Stern, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 1, 1989
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuationsP A Kempster, W R Gibb, G M Stern, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 1, 1990
Comparison of motor response to apomorphine and levodopa in Parkinson's diseaseP A Kempster, J P Frankel, G M Stern, et al.Lancet (London, England)|February 20, 1988
Subcutaneous apomorphine in parkinsonian on-off oscillationsC M Stibe, A J Lees, P A Kempster, et al.Journal of Neural Transmission|January 1, 1983
Platelet phenolsulphotransferase activity in Parkinson's diseaseV Glover, A J Lees, C Ward, et al.Brain : a Journal of Neurology|June 1, 1987
Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental studyD Rogers, A J Lees, E Smith, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1990
Subcutaneous apomorphine in the treatment of Parkinson's diseaseJ P Frankel, A J Lees, P A Kempster, et al.Journal of Neural Transmission|January 1, 1982
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian propertiesJ D Elsworth, M Sandler, A J Lees, et al.Pageof 35